JNPMEDI, a clinical trial consulting and platform company, announced on Wednesday that it is advancing in the Korean decentralized clinical trial (DCT) market with its clinical trial data collection and monitoring solution, Maven eCOA.

Maven eCOA minimizes patient data entry errors and helps researchers maintain data accuracy and consistency. It also promotes patient survey participation with its user-friendly interface and notification features, while enabling researcher-patient data linkage and real-time monitoring.

JNPMEDI has applied Maven eCOA to clinical trials for products such as Welt's insomnia digital therapy device, WELT-I, and EverEx's musculoskeletal rehabilitation exercise digital therapy device, MORA Cure.

In particular, JNPMEDI highlighted that the Maven eCOA solution was used in EverEx's MORA Cure confirmatory clinical trial to collect efficacy and safety data, enhancing the patient-centered clinical environment and improving convenience.

“JNPMEDI will continue to develop DCT-based clinical trial solutions, such as Maven eCOA, to expand both domestic and international markets,” said Kwunho Jeong, CEO of JNPMEDI. “We will collaborate with various companies to establish ourselves as a leading player in the domestic DCT market.”

Decentralized clinical trials (DCTs) are expanding globally due to their benefits of reducing trial costs and enhancing participant convenience. In Korea, the Korea National Enterprise for Clinical Trials (KoNECT) launched a pilot DCT project in December last year to develop new technologies for DCTs.